Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial

Alexander Peikert,Bradley A. Bart,Muthiah Vaduganathan,Brian L. Claggett,Ian J. Kulac,Mikhail N. Kosiborod,Akshay S. Desai,Pardeep S. Jhund,Carolyn S.P. Lam,Silvio E. Inzucchi,Felipe A. Martinez,Rudolf A. de Boer,Adrian F. Hernandez,Sanjiv J. Shah,Magnus Petersson,Anna Maria Langkilde,John J.V. McMurray,Scott D. Solomon,Orly Vardeny

JACC. Heart failure（2023）

引用 0|浏览4

暂无评分

摘要

In patients with HFmrEF or HFpEF enrolled in DELIVER, 4 out of 5 participants were treated with a beta-blocker. Beta-blocker use was not associated with a higher risk of worsening HF or cardiovascular death. Dapagliflozin consistently and safely reduced clinical events, irrespective of background beta-blocker use.

查看译文

关键词

beta-blockers,heart failure with mildly reduced ejection fraction,heart failure with preserved ejection fraction,SGLT2 inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要